Metraipolis › archive › dc_8d445a2896a4

Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure — Europe PMC PMID:41385077

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41385077
DOI: 10.1007/s00467-[numero omesso]-6
License (as archived): solo-consultazione
Archived: 2026-11-07T16:56:40.544Z
SHA-256 of the archived text: d393636315785cde8b61925e0343bb921eaaffadb78f507aaac9e3334e52f021
Stable URL of this page: https://metraipolis.com/documento/dc_8d445a2896a4

How to cite

Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure — Europe PMC PMID:41385077 — Europe PMC (en), https://europepmc.org/article/MED/41385077 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8d445a2896a4 (Metraipolis archive dc_8d445a2896a4, sha256 d393636315785cde8b61925e0343bb921eaaffadb78f507aaac9e3334e52f021)

BibTeX

@misc{dc8d445a2896a4,
  title = {Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure — Europe PMC PMID:41385077},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41385077},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8d445a2896a4; sha256 d393636315785cde8b61925e0343bb921eaaffadb78f507aaac9e3334e52f021},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41385077. Agents can read the archived copy with the MCP tool read_document.